Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas R Gantenbein

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Therapeutische Umschau. Revue Therapeutique|July 3, 2025
Andreas R Gantenbein
Cephalalgia : an International Journal of Headache|February 10, 2025
Depression screening in migraine - A double-edged swordAndreas R Gantenbein
Praxis|March 17, 2021
[COVID-19 and Headaches]Heiko Pohl, Andreas R Gantenbein
The Journal of Headache and Pain|March 30, 2023
Is the right way to go in between? : Rimegepant as needed provides preventive benefit. A comment on: monthly migraine days, tablet utilization, and quality of life associated with rimegepant-post hoc results from an open label safety study (BHV3000-201)Andreas R Gantenbein, Andreas Kleinschmidt
Handbook of Clinical Neurology|February 2, 2024
Nutraceuticals in migraineThilinie Rajapakse, Andreas R Gantenbein
Cephalalgia : an International Journal of Headache|May 23, 2025
Philosophical aspects of migraine: Headache treatment is a human-to-human serviceMark J Emmenegger, Andreas R Gantenbein
Therapeutische Umschau. Revue Therapeutique|April 3, 2019
[Migraine prophylaxis 2019 - the role of CGRP antagonists]Peter S Sandor, Andreas R Gantenbein
Headache|July 27, 2006
Physiological parameters as biomarkers of migraineAndreas R Gantenbein, Peter S Sándor
Asian Biomedicine : Research, Reviews and News|August 8, 2023
Importance of quantifying migraine disability in the native language of the migraineurAndreas R Gantenbein, Robin James Storer
Current Pain and Headache Reports|November 18, 2019
Can Anything Good Ever Come From Bearing Migraine Attacks? Suggestions for a Comprehensive Concept of Gain in MigraineHeiko Pohl, Maximilian Schubring-Giese, Andreas R Gantenbein
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Therapeutische Umschau. Revue Therapeutique|July 3, 2025
Andreas R Gantenbein
Cephalalgia : an International Journal of Headache|February 10, 2025
Depression screening in migraine - A double-edged swordAndreas R Gantenbein
Praxis|March 17, 2021
[COVID-19 and Headaches]Heiko Pohl, Andreas R Gantenbein
The Journal of Headache and Pain|March 30, 2023
Is the right way to go in between? : Rimegepant as needed provides preventive benefit. A comment on: monthly migraine days, tablet utilization, and quality of life associated with rimegepant-post hoc results from an open label safety study (BHV3000-201)Andreas R Gantenbein, Andreas Kleinschmidt
Handbook of Clinical Neurology|February 2, 2024
Nutraceuticals in migraineThilinie Rajapakse, Andreas R Gantenbein
Cephalalgia : an International Journal of Headache|May 23, 2025
Philosophical aspects of migraine: Headache treatment is a human-to-human serviceMark J Emmenegger, Andreas R Gantenbein
Therapeutische Umschau. Revue Therapeutique|April 3, 2019
[Migraine prophylaxis 2019 - the role of CGRP antagonists]Peter S Sandor, Andreas R Gantenbein
Headache|July 27, 2006
Physiological parameters as biomarkers of migraineAndreas R Gantenbein, Peter S Sándor
Asian Biomedicine : Research, Reviews and News|August 8, 2023
Importance of quantifying migraine disability in the native language of the migraineurAndreas R Gantenbein, Robin James Storer
Current Pain and Headache Reports|November 18, 2019
Can Anything Good Ever Come From Bearing Migraine Attacks? Suggestions for a Comprehensive Concept of Gain in MigraineHeiko Pohl, Maximilian Schubring-Giese, Andreas R Gantenbein
Pageof 9